Aging involves gradual functional decline across various biological systems, including impaired cellular mechanisms such as ...
Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...
Aaron Samson was home caring for his 83-year-old father-in-law, who has Parkinson’s Disease, in the Pacific Palisades when he got an alert about a wildfire. While in traffic, Samson and his father-in- ...
Research highlights the therapeutic potential of targeting cannabinoid receptors to counter memory impairment in early ...
Hamilton Centre MP Matthew Green and McMaster University researcher Tracy Prowse have joined Canadian researchers and PETA in ...
Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the ...
Neumirna Therapeutics has raised €20m to develop microRNA therapies for epilepsy and other neurological conditions.
Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated th ...
X-tosis, Inc., a pre-clinical biotech company transforming the treatment of neurodegenerative and mitochondrial ...